

Abstracts

exposure. Severe fetal thrombocytopenia was noted at the time of cordocentesis. Repeated intrauterine transfusions were required however fetal cardiac function deteriorated further which resulted in fetal demise.

Case 2: The second cases involved a 32 year old multip with confirmed Parvovirus infection who was referred with severe fetal hydrops. Severe thrombocytopenia was again noted however a successful fetal transfusion was performed. Unfortunately the mother subsequently developed Ballantyne (Mirror) syndrome which resolved with expectant management.

Case 3: The final case involved a 28 year old multip with a dichorionic twin pair both of which were severely anaemic with similar haematocrit levels at cordocentesis. Both twins received the same treatment course however different outcomes were encountered.

This case series demonstrates the various complications that add further challenging features to the management of pregnancies affected by Parvovirus infection.

PF.65 WITHDRAWN BY AUTHOR

PF.66 PROGNOSTIC SIGNIFICANCE AN ENLARGED FETAL STOMACH IN THE SECOND TRIMESTER

doi:10.1136/archdischild-2013-303966.074

J Richardson, S Boxall, J Stanwell, D Wellesley, K Brackley. *University Hospital Southampton NHS Foundation Trust, Southampton, UK*

Introduction Duodenal atresia classically presents with a “double bubble” sign and polyhydramnios in the third trimester. The significance of an enlarged stomach detected on a second trimester scan is unclear.

Methods A retrospective review of cases identified from the Wessex Fetal Medicine and Antenatally Detected Anomaly (WANDA) regional databases from 1995 to 2012. Scan reports were reviewed and correlated with outcome.

Results 33 cases of an enlarged stomach in the second trimester were identified. In nine there were additional major anomalies: four with gastroschisis, three with cardiac anomalies (including two trisomies), one severe growth restriction with dilated bowel loops and one with renal cystic dysplasia. In the 24 fetuses without additional major anomalies, five had early signs of a “double bubble” with the first part of the duodenum visible. Three (60%) had confirmed duodenal atresia after delivery, one with VATER syndrome and one with trisomy 21. In the 19 cases without an early “double bubble” sign, stomach enlargement resolved in eight (42%) and persisted in 11 (58%), one with polyhydramnios. In these 19 babies there was one neonatal death following preterm labour at 26 weeks post amniocentesis. In the 18 cases with postnatal follow up, there were no gastro-intestinal anomalies or feeding problems detected.

Conclusions The finding of an isolated enlarged stomach in the second trimester appears to have a good outcome with no associated feeding problems. However if an early “double bubble” sign is seen there is a significant risk of an underlying duodenal atresia.

PF.67 THE INCREASED INCIDENCE OF ECHOGENIC LUNG LESIONS – AN 18-YEAR REVIEW FROM THE WESSEX REGION

doi:10.1136/archdischild-2013-303966.075

¹LJ Stocker, ²D Wellesley, ²R Parasuraman, ²DT Howe. *¹University of Southampton, Southampton, UK; ²University Hospitals Southampton NHS Trust, Southampton, UK*

Introduction Echogenic lung lesions (ELL) are a heterogeneous group of lung abnormalities that display a variety of features and are inherently difficult to diagnose and characterise antenatally. Included in this group are congenital cystic adenomatoid malformations (CCAM), pulmonary sequestration, broncho-pulmonary atresia, and congenital emphysema.

Objectives To investigate the changing incidence of echogenic lung lesions detected both antenatally and postnatally.

Methods A retrospective review of cases identified from the Fetal Medicine database and the Wessex Antenatally Detected Anomalies (WANDA) congenital anomalies register from 1994 to 2011.

Results We identified a total of 111 cases of ELL in 492,559 births during the stated period. All but six cases were identified on antenatal ultrasound.

In 1994, the total incidence of ELL was 0.37 per 10 000 births. By 2011 this had risen to 5.39 per 10 000 births, with a progressive incline during the intervening years.

Conclusion We found a nearly 15-fold increase in the incidence of ELL found antenatally in the Wessex region between 1994 and 2011. It is unclear whether this is due to a true rise in the incidence of this abnormality, or due to increased antenatal recognition as a result of improved ultrasound resolution and operator experience.

PF.68 TORCH SCREENING, WHERE ARE WE NOW?

doi:10.1136/archdischild-2013-303966.076

¹SM Halawa, ¹L McDermott, ¹ML Denbow, ^{1,2}M Donati. *¹United Hospitals Bristol NHS trust, Bristol, UK; ²Public Health Laboratory, Bristol, UK*

TORCH screening is used in pregnancy in a wide number of indications. In 1990 the Public Health Laboratory service advised that individual serology tests, rather than a TORCH screen, should be performed depending upon clinical circumstances^{1,2}. Our group confirmed these findings for fetal medicine indications.¹ The aim of this retrospective study was to determine our progress with the use of TORCH in pregnancy.

Methods A retrospective review of all TORCH tests requested in St Michael's Hospital in obstetrics and gynaecology between 01/10/2006 and 31/01/2012 was undertaken via the pathology database.

Results 742 tests were undertaken over the study period. 40 indications were identified. There were 4 positive tests for CMV (1%), with no cases of confirmed toxoplasmosis or rubella. CMV was found in late miscarriage, recurrent miscarriage and multiple fetal abnormality.

Conclusions The incidence of toxoplasma in the UK is 1–2 infections per 1000 pregnancies³ and is normally associated with a maternal illness. Rubella is screened for as part of the routine antenatal screen. Our findings have further confirmed the targeted approach to serology screening⁴. We therefore now only perform CMV serology unless there is an overwhelming clinical indication for the addition of toxoplasma testing.

REFERENCES

1. Abdel-Fattah SA, Bhat A, Illanes S, *et al*. TORCH test for fetal medicine indications; only CMV is necessary in the UK. *Prenat Diagn* 2005;25:1028-31.
2. PHLS. TORCH screening reassessed: the laboratory investigation of congenital, perinatal and neonatal infection. 1. UK: Public Health Laboratory Service, 1990.
3. Allain JP, Palmer CR, Pearson G. Epidemiological study of latent and recent infection by Toxoplasmosis Gondii in pregnant women in a regional population in the UK. *J Infect* 1998;36:189-96.
4. Fayyaz H, Rafi J. TORCH screening in polyhydramnios: an observational study. *J Matern Fetal Neonatal Med* 2012;25:1069-72.

PF.69 IRELAND'S NATIONAL PERINATAL NEUROSURGICAL CLINIC: REFERRAL PATTERNS AND OUTCOMES, 2010–2012

doi:10.1136/archdischild-2013-303966.077

¹CA Walsh, ^{1,4}FM McAuliffe, ²D Crimmins, ³E Laffan, ³V Donoghue, ¹S Higgins, ¹R Mahony, ¹S Carroll, ¹P McParland. *¹Department of Fetal Medicine, National Maternity Hospital, Dublin, Ireland; ²Department of Paediatric Neurosurgery, Children's University Hospital, Dublin, Ireland; ³Department of Paediatric Radiology, National Maternity Hospital, Dublin, Ireland; ⁴UCD School of Medicine and Medical Sciences, Dublin, Ireland*



PF.68 TORCH Screening, Where Are We Now?

SM Halawa, L McDermott, ML Denbow and M Donati

Arch Dis Child Fetal Neonatal Ed 2013 98: A22
doi: 10.1136/archdischild-2013-303966.076

Updated information and services can be found at:
http://fn.bmj.com/content/98/Suppl_1/A22.3

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Screening \(epidemiology\)](#) (234)
[Screening \(public health\)](#) (234)
[Travel medicine](#) (11)
[Tropical medicine \(infectious diseases\)](#) (12)
[Pregnancy](#) (1521)
[Reproductive medicine](#) (1433)
[Epidemiologic studies](#) (929)
[Obstetrics and gynaecology](#) (396)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>